Cite
HARVARD Citation
Ball, B. et al. (2022). Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leukemia & lymphoma. 63 (13), pp. 3232-3236. [Online].